-
Mashup Score: 2
Since cabazitaxel improved pain response, time to pain progression, time to symptomatic skeletal events, and EQ-5D-5L utility index, clinicians and patients with metastatic castration-resistant prostate cancer can be reassured that cabazitaxel will not reduce quality of life when compared with treatment with a second androgen signalling-targeted inhibitor.
Source: The Lancet OncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0
Neal Shore, MD, FACS joins Alicia Morgans, MD, MPH to discuss the outcomes of the CARD trial, Cabazitaxel Versus the Switch to Alternative AR-targeted Agent (Enzalutamide or Abiraterone) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Patients Previously Treated With Docetaxel and Who Rapidly Failed a Prior AR-targeted Agent (CARD) in a recent analysis presented at the AUA 2020…
Source: UroTodayCategories: General Medicine News, Latest HeadlinesTweet-
Effect of #cabazitaxel vs abi or enza on patient-reported outcomes in #mCRPC: A pre-planned EQ-5D-5L analysis of the #CARD study. Neal Shore, MD, FACS @AtlanticUrology joins @CaPsurvivorship @NUFeinbergMed in a discussion on UroToday > https://t.co/445Pz506Oy @sanofi https://t.co/0LqPr0BSSW
-
-
Mashup Score: 0
Neal Shore, MD, FACS joins Alicia Morgans, MD, MPH to discuss the outcomes of the CARD trial, Cabazitaxel Versus the Switch to Alternative AR-targeted Agent (Enzalutamide or Abiraterone) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Patients Previously Treated With Docetaxel and Who Rapidly Failed a Prior AR-targeted Agent (CARD) in a recent analysis presented at the AUA 2020…
Source: UroTodayCategories: Latest Headlines, UrologyTweet-
Effect of #cabazitaxel vs abi or enza on patient-reported outcomes in #mCRPC: A pre-planned EQ-5D-5L analysis of the #CARD study. Neal Shore, MD, FACS @AtlanticUrology joins @CaPsurvivorship @NUFeinbergMed in a discussion on UroToday > https://t.co/445Pz506Oy @sanofi https://t.co/R0KMW9DflM
-
-
Mashup Score: 0
Neal Shore, MD, FACS joins Alicia Morgans, MD, MPH to discuss the outcomes of the CARD trial, Cabazitaxel Versus the Switch to Alternative AR-targeted Agent (Enzalutamide or Abiraterone) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Patients Previously Treated With Docetaxel and Who Rapidly Failed a Prior AR-targeted Agent (CARD) in a recent analysis presented at the AUA 2020…
Source: UroTodayCategories: Latest Headlines, UrologyTweet-
Effect of #cabazitaxel vs abi or enza on patient-reported outcomes in #mCRPC: A pre-planned EQ-5D-5L analysis of the #CARD study. Neal Shore, MD, FACS @AtlanticUrology joins @CaPsurvivorship @NUFeinbergMed in a discussion on UroToday > https://t.co/445Pz506Oy @sanofi https://t.co/OdxVogTSRL
-
-
Mashup Score: 0JNCCN 360 - 4 year(s) ago
By: Kayci Reyer Posted: Friday, June 5, 2020 According to findings from the TheraP trial, presented during the ASCO20 Virtual Scientific Program (Abstract 5500), lutetium Lu 177–prostate-specific membrane antigen–617 (LuPSMA) may result in survival benefits for patients whose metastatic castration-resistant…
Source: jnccn360.orgCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
#ASCO20: #LuPSMA vs. #cabazitaxel in metastatic castration-resistant #prostatecancer: https://t.co/OR1HTi7g5n #PCSM #JNCCN360 https://t.co/tCOZh9wrJO
-
Online first: #Qualityoflife in patients with metastatic #prostatecancer following treatment with #cabazitaxel versus #abiraterone or #enzalutamide—results from the CARD study #pcsm https://t.co/s2eZHUe8UQ